Clive Page

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6873213/publications.pdf

Version: 2024-02-01

133	5,448	94433	91884
papers	citations	37 h-index	69 g-index

134	134	134	6552
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Pharmacology and Therapeutics of Bronchodilators. Pharmacological Reviews, 2012, 64, 450-504.	16.0	379
2	Phosphodiesterase inhibitors. British Journal of Pharmacology, 2006, 147, S252-7.	5.4	338
3	Pharmacology of Heparin and Related Drugs. Pharmacological Reviews, 2016, 68, 76-141.	16.0	250
4	Platelets are essential for leukocyte recruitment in allergic inflammation. Journal of Allergy and Clinical Immunology, 2003, 112, 109-118.	2.9	197
5	Platelet P-selectin is required for pulmonary eosinophil and lymphocyte recruitment in a murine model of allergic inflammation. Blood, 2005, 105, 2074-2081.	1.4	190
6	Animal models of mechanisms of <scp>SARSâ€CoVâ€2</scp> infection and <scp>COVIDâ€19</scp> pathology. British Journal of Pharmacology, 2020, 177, 4851-4865.	5.4	158
7	Allergen Induces the Migration of Platelets to Lung Tissue in Allergic Asthma. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 604-612.	5.6	147
8	Influence ofN-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. European Respiratory Review, 2015, 24, 451-461.	7.1	140
9	Circulating platelet-neutrophil complexes are important for subsequent neutrophil activation and migration. Journal of Applied Physiology, 2010, 109, 758-767.	2.5	136
10	The effect of N -acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections. Respiratory Medicine, 2016, 117, 190-197.	2.9	136
11	Platelets are necessary for airway wall remodeling in a murine model of chronic allergic inflammation. Blood, 2004, 103, 639-647.	1.4	135
12	Selective PDE inhibitors as novel treatments for respiratory diseases. Current Opinion in Pharmacology, 2012, 12, 275-286.	3.5	128
13	Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. Lancet Respiratory Medicine,the, 2013, 1, 714-727.	10.7	121
14	Neutrophil and platelet complexes and their relevance to neutrophil recruitment and activation. International Immunopharmacology, 2013, 17, 1176-1184.	3.8	106
15	The effects of heparin and related molecules upon the adhesion of human polymorphonuclear leucocytes to vascular endothelium in vitro. British Journal of Pharmacology, 2000, 129, 533-540.	5.4	94
16	The Requirement for Platelets in Allergen-induced Late Asthmatic Airway Obstruction: Eosinophil Infiltration and Heightened Airway Responsiveness in Allergic Rabbits. The American Review of Respiratory Disease, 1990, 142, 587-593.	2.9	89
17	Fucosylated Chondroitin Sulfates from the Body Wall of the Sea Cucumber Holothuria forskali. Journal of Biological Chemistry, 2014, 289, 28284-28298.	3.4	88
18	Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence. Critical Care, 2020, 24, 454.	5.8	81

#	Article	IF	Citations
19	Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi. European Journal of Pharmacology, 2014, 745, 135-143.	3.5	80
20	P-Rex and Vav Rac-GEFs in platelets control leukocyte recruitment to sites of inflammation. Blood, 2015, 125, 1146-1158.	1.4	76
21	Unfractionated heparin inhibits live wild type SARSâ€CoVâ€2 cell infectivity at therapeutically relevant concentrations. British Journal of Pharmacology, 2021, 178, 626-635.	5.4	73
22	Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. European Respiratory Journal, 2017, 50, 1700711.	6.7	68
23	Role of platelets in allergic airway inflammation. Journal of Allergy and Clinical Immunology, 2015, 135, 1416-1423.	2.9	66
24	Long-acting muscarinic receptor antagonists for the treatment of respiratory disease. Pulmonary Pharmacology and Therapeutics, 2013, 26, 307-317.	2.6	65
25	RhoA signaling through platelet P2Y1 receptor controls leukocyte recruitment in allergic mice. Journal of Allergy and Clinical Immunology, 2015, 135, 528-538.e4.	2.9	60
26	Heparin and Related Drugs: Beyond Anticoagulant Activity. ISRN Pharmacology, 2013, 2013, 1-13.	1.6	59
27	Phosphodiesterase Inhibitors for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease. International Archives of Allergy and Immunology, 2014, 165, 152-164.	2.1	57
28	Platelet Depletion Impairs Host Defense to Pulmonary Infection with Pseudomonas aeruginosa in Mice. American Journal of Respiratory Cell and Molecular Biology, 2018, 58, 331-340.	2.9	55
29	Brain natriuretic peptide: Much more than a biomarker. International Journal of Cardiology, 2016, 221, 1031-1038.	1.7	51
30	Doxofylline: A â€œNovofyllineâ€• Pulmonary Pharmacology and Therapeutics, 2010, 23, 231-234.	2.6	49
31	Bifunctional drugs for the treatment of asthma and chronic obstructive pulmonary disease. European Respiratory Journal, 2014, 44, 475-482.	6.7	48
32	Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: Synergy of triple combination therapy on human airway smooth muscle ex vivo. British Journal of Pharmacology, 2020, 177, 1150-1163.	5.4	47
33	Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways. Pulmonary Pharmacology and Therapeutics, 2015, 32, 15-23.	2.6	46
34	Targeting Mechanisms Linking COPD to Type 2 Diabetes Mellitus. Trends in Pharmacological Sciences, 2017, 38, 940-951.	8.7	46
35	Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine. Respiratory Research, 2019, 20, 104.	3.6	45
36	Prospects for COPD treatment. Current Opinion in Pharmacology, 2021, 56, 74-84.	3.5	45

#	Article	IF	Citations
37	Thiol-Based Drugs in Pulmonary Medicine: Much More than Mucolytics. Trends in Pharmacological Sciences, 2019, 40, 452-463.	8.7	42
38	Effects of bradykinin receptor antagonists on antigenâ€induced respiratory distress, airway hyperresponsiveness and eosinophilia in guineaâ€pigs. British Journal of Pharmacology, 1992, 107, 653-659.	5.4	40
39	Nonantimicrobial Actions of Macrolides: Overview and Perspectives for Future Development. Pharmacological Reviews, 2021, 73, 1404-1433.	16.0	40
40	Doxofylline is not just another theophylline!. International Journal of COPD, 2017, Volume 12, 3487-3493.	2.3	39
41	Inhaled nebulised unfractionated heparin improves lung function in moderate to very severe COPD: A pilot study. Pulmonary Pharmacology and Therapeutics, 2018, 48, 88-96.	2.6	39
42	Heparanase induces inflammatory cell recruitment in vivo by promoting adhesion to vascular endothelium. American Journal of Physiology - Cell Physiology, 2014, 306, C1184-C1190.	4.6	38
43	LPS-induced Lung Platelet Recruitment Occurs Independently from Neutrophils, PSGL-1, and P-Selectin. American Journal of Respiratory Cell and Molecular Biology, 2019, 61, 232-243.	2.9	38
44	Heparin and non-anticoagulant heparin attenuate histone-induced inflammatory responses in whole blood. PLoS ONE, 2020, 15, e0233644.	2.5	37
45	The rabbit as a model to study asthma and other lung diseases. Pulmonary Pharmacology and Therapeutics, 2008, 21, 721-730.	2.6	36
46	Therapeutic Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease. Drugs, 2016, 76, 1257-1270.	10.9	36
47	Plateletâ€“Eosinophil Interactions As a Potential Therapeutic Target in Allergic Inflammation and Asthma. Frontiers in Medicine, 2017, 4, 129.	2.6	36
48	Effect of heparin and a lowâ€molecular weight heparinoid on PAFâ€induced airway responses in neonatally immunized rabbits. British Journal of Pharmacology, 1993, 110, 107-112.	5.4	35
49	The Role of Heparanase in Pulmonary Cell Recruitment in Response to an Allergic but Not Non-Allergic Stimulus. PLoS ONE, 2015, 10, e0127032.	2.5	35
50	Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients. Respiratory Medicine, 2019, 154, 86-92.	2.9	35
51	Some structural determinants of the antiproliferative effect of heparin-like molecules on human airway smooth muscle. British Journal of Pharmacology, 2005, 146, 370-377.	5.4	31
52	Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases. Drugs, 2017, 77, 721-732.	10.9	29
53	The Effect of Phytocannabinoids on Airway Hyper-Responsiveness, Airway Inflammation, and Cough. Journal of Pharmacology and Experimental Therapeutics, 2015, 353, 169-180.	2.5	28
54	Doxofylline, a novofylline inhibits lung inflammation induced by lipopolysacharide in the mouse. Pulmonary Pharmacology and Therapeutics, 2014, 27, 170-178.	2.6	26

#	Article	IF	Citations
55	Î²2-Adrenoceptor signalling bias in asthma and COPD and the potential impact on the comorbidities associated with these diseases. Current Opinion in Pharmacology, 2018, 40, 142-146.	3.5	24
56	The anti-inflammatory effects of cannabidiol and cannabigerol alone, and in combination. Pulmonary Pharmacology and Therapeutics, 2021, 69, 102047.	2.6	24
57	The effects of heparin on the adhesion of human peripheral blood mononuclear cells to human stimulated umbilical vein endothelial cells. British Journal of Pharmacology, 2001, 134, 827-836.	5.4	23
58	Pathogenesis of COPD and Asthma. Handbook of Experimental Pharmacology, 2016, 237, 1-21.	1.8	23
59	Effect of Erdosteine on COPD Exacerbations in COPD Patients with Moderate Airflow Limitation . International Journal of COPD, 2019, Volume 14, 2733-2744.	2.3	23
60	Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of respiratory disease. Expert Opinion on Investigational Drugs, 2006, 15, 1105-1113.	4.1	22
61	Effect of a 5â€lipoxygenase inhibitor and leukotriene antagonist (PF 5901) on antigenâ€induced airway responses in neonatally immunized rabbits. British Journal of Pharmacology, 1994, 112, 292-298.	5.4	21
62	Pharmacological characterization of the interaction between tiotropium bromide and olodaterol on human bronchi and small airways. Pulmonary Pharmacology and Therapeutics, 2019, 56, 39-50.	2.6	21
63	Multifaceted Beneficial Effects of Erdosteine: More than a Mucolytic Agent. Drugs, 2020, 80, 1799-1809.	10.9	21
64	Contribution of sensory nerves to LPS-induced hyperresponsiveness of human isolated bronchi. Life Sciences, 2015, 131, 44-50.	4.3	20
65	A Non-Anticoagulant Fraction of Heparin Inhibits Leukocyte Diapedesis into the Lung by an Effect on Platelets. American Journal of Respiratory Cell and Molecular Biology, 2016, 55, 554-563.	2.9	20
66	Bifunctional Drugs for the Treatment of Respiratory Diseases. Handbook of Experimental Pharmacology, 2016, 237, 197-212.	1.8	20
67	Predicting the Fine Particle Fraction of Dry Powder Inhalers Using Artificial Neural Networks. Journal of Pharmaceutical Sciences, 2017, 106, 313-321.	3.3	20
68	Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis. Pulmonary Pharmacology and Therapeutics, 2018, 48, 185-194.	2.6	20
69	Effect of a 5â€lipoxygenase inhibitor and leukotriene antagonist (PF 5901) on PAFâ€induced airway responses in neonatally immunized rabbits. British Journal of Pharmacology, 1992, 107, 1108-1115.	5.4	19
70	Diverse signalling of the platelet P2Y1 receptor leads to a dichotomy in platelet function. European Journal of Pharmacology, 2018, 827, 58-70.	3.5	19
71	INHALEd nebulised unfractionated HEParin for the treatment of hospitalised patients with COVIDâ€19 (INHALEâ€HEP): Protocol and statistical analysis plan for an investigatorâ€initiated international metatrial of randomised studies. British Journal of Clinical Pharmacology, 2021, 87, 3075-3091.	2.4	19
72	Pharmacology of a new cyclic nucleotide phosphodiesterase type 4 inhibitor, V11294. Pulmonary Pharmacology and Therapeutics, 2003, 16, 97-104.	2.6	18

#	Article	IF	Citations
73	Steroid sparing effects of doxofylline. Pulmonary Pharmacology and Therapeutics, 2018, 48, 1-4.	2.6	18
74	A dichotomy in platelet activation: Evidence of different functional platelet responses to inflammatory versus haemostatic stimuli. Thrombosis Research, 2018, 172, 110-118.	1.7	18
75	Platelets Independently Recruit into Asthmatic Lungs and Models of Allergic Inflammation via CCR3. American Journal of Respiratory Cell and Molecular Biology, 2021, 64, 557-568.	2.9	18
76	Paradoxical pharmacology: turning our pharmacological models upside down. Trends in Pharmacological Sciences, 2011, 32, 197-200.	8.7	17
77	Impact of doxofylline in COPD: A pairwise meta-analysis. Pulmonary Pharmacology and Therapeutics, 2018, 51, 1-9.	2.6	17
78	Inhaled nebulised unfractionated heparin for the treatment of hospitalised patients with COVIDâ€19: A multicentre case series of 98 patients. British Journal of Clinical Pharmacology, 2022, 88, 2802-2813.	2.4	17
79	Adenosine monophosphate is elevated in the bronchoalveolar lavage fluid of mice with acute respiratory toxicity induced by nanoparticles with high surface hydrophobicity. Nanotoxicology, 2015, 9, 106-115.	3.0	16
80	Role of glycosaminoglycans in inflammation. Inflammopharmacology, 2001, 9, 165-169.	3.9	15
81	Use of indacaterol for the treatment of COPD: a pharmacokinetic evaluation. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 129-137.	3.3	15
82	Lung inflammation does not affect the clearance kinetics of lipid nanocapsules following pulmonary administration. Journal of Controlled Release, 2016, 235, 24-33.	9.9	15
83	Ozone-Induced Hypertussive Responses in Rabbits and Guinea Pigs. Journal of Pharmacology and Experimental Therapeutics, 2016, 357, 73-83.	2.5	15
84	Sex differences in the influence of obesity on a murine model of allergic lung inflammation. Clinical and Experimental Allergy, 2020, 50, 256-266.	2.9	15
85	Î²₂-Agonists and Bronchial Hyperresponsiveness. Clinical Reviews in Allergy and Immunology, 2006, 31, 143-162.	6.5	14
86	Platelets Play a Central Role in Sensitization to Allergen. American Journal of Respiratory Cell and Molecular Biology, 2018, 59, 96-103.	2.9	14
87	Regulation of platelet function by catecholamines in the cerebral vasculature of the rabbit. British Journal of Pharmacology, 1999, 127, 1652-1656.	5.4	13
88	Base-modified UDP-sugars reduce cell surface levels of P-selectin glycoprotein 1 (PSGL-1) on IL-1Î²-stimulated human monocytes. Glycobiology, 2016, 26, 1059-1071.	2.5	13
89	Ensifentrine (RPL554): an inhaled â€˜bifunctionalâ€™ dual PDE3/4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease. Pharmaceutical Patent Analyst, 2018, 7, 249-257.	1.1	13
90	Antitussive effect of carcainium chloride in patients with chronic cough and idiopathic interstitial pneumonias: A pilot study. Pulmonary Pharmacology and Therapeutics, 2016, 40, 91-94.	2.6	11

#	Article	IF	Citations
91	Long-Acting Î²2-Agonists in Asthma: Enantioselective Safety Studies are Needed. Drug Safety, 2018, 41, 441-449.	3.2	11
92	Comparison of Oral, Intranasal and Aerosol Administration of Amiodarone in Rats as a Model of Pulmonary Phospholipidosis. Pharmaceutics, 2019, 11, 345.	4.5	11
93	Structural characterization and anti-inflammatory activity of two novel polysaccharides from the sea squirt, Ascidiella aspersa. Pulmonary Pharmacology and Therapeutics, 2016, 40, 69-79.	2.6	10
94	Pharmacokinetic considerations concerning the use of bronchodilators in the treatment of chronic obstructive pulmonary disease. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 1101-1111.	3.3	10
95	Antitussive therapy: A role for levodropropizine. Pulmonary Pharmacology and Therapeutics, 2019, 56, 79-85.	2.6	10
96	Dual bronchodilation for the treatment of COPD: From bench to bedside. British Journal of Clinical Pharmacology, 2022, 88, 3657-3673.	2.4	10
97	Effects of dopamine and selective dopamine agonists upon platelet accumulation in the cerebral and pulmonary vasculature of the rabbit. British Journal of Pharmacology, 1997, 122, 682-686.	5.4	9
98	Effects of dexamethasone on airway hyper-responsiveness to the adenosine A1 receptor agonist cyclo-pentyl adenosine in an allergic rabbit model. British Journal of Pharmacology, 1999, 126, 1513-1521.	5.4	9
99	Models used in the development of antitussive drugs. Drug Discovery Today: Disease Models, 2004, 1, 297-302.	1.2	9
100	An inhaled â€œbifunctionalâ€•dual PDE3/4 inhibitor provides additional short-term improvements in lung function compared to existing classes of bronchodilator: implications for future treatment of COPD. European Respiratory Journal, 2018, 52, 1801675.	6.7	9
101	Can nebulised HepArin Reduce morTality and time to Extubation in patients with COVIDâ€19 Requiring invasive ventilation Metaâ€Trial (CHARTERâ€MT): Protocol and statistical analysis plan for an investigatorâ€initiated international metaâ€trial of prospective randomised clinical studies. British Journal of Clinical Pharmacology, 2022, 88, 3272-3287.	2.4	9
102	A comparison of allergen and polycation induced cutaneous responses in the rabbit. British Journal of Pharmacology, 2001, 133, 1181-1189.	5.4	8
103	Update on animal models for COVIDâ€19 research. British Journal of Pharmacology, 2020, 177, 5679-5681.	5.4	8
104	Interaction of Formulation and Device Factors Determine the In Vitro Performance of Salbutamol Sulphate Dry Powders for Inhalation. Journal of Pharmaceutical Sciences, 2015, 104, 3861-3869.	3.3	7
105	Effect of lipopolysaccharide on the responsiveness of equine bronchial tissue. Pulmonary Pharmacology and Therapeutics, 2018, 49, 88-94.	2.6	7
106	Modulation of allergic inflammation in the lung by a peptide derived from Mycobacteria tuberculosis chaperonin 60.1. Clinical and Experimental Allergy, 2020, 50, 508-519.	2.9	7
107	Novel pharmacological therapies for the treatment of bronchial asthma. Minerva Medica, 2022, 113, .	0.9	7
108	Sir <scp>D</scp>avid <scp>J</scp>ack: an extraordinary drug discoverer and developer. British Journal of Clinical Pharmacology, 2013, 75, 1213-1218.	2.4	6

#	Article	IF	Citations
109	Using Salt Counterions to Modify Î²₂-Agonist Behavior in Vivo. Molecular Pharmaceutics, 2016, 13, 3439-3448.	4.6	6
110	Effect of PF 10040 on PAFâ€induced airway responses in neonatally immunized rabbits. British Journal of Pharmacology, 1994, 111, 7-12.	5.4	5
111	A new model for the continuous monitoring of polymorphonuclear leukocyte trapping in the pulmonary vasculature of the rabbit. Journal of Pharmacological and Toxicological Methods, 2002, 48, 21-29.	0.7	5
112	Extracellular matrix composition influences the resistance of airway remodelling events towards glucocorticoid treatment. British Journal of Pharmacology, 2003, 138, 1181-1182.	5.4	5
113	Mechanisms of acute cough. Pulmonary Pharmacology and Therapeutics, 2004, 17, 389-391.	2.6	5
114	Biochemical and functional characterization of glycosaminoglycans released from degranulating rat peritoneal mast cells: Insights into the physiological role of endogenous heparin. Pulmonary Pharmacology and Therapeutics, 2016, 41, 96-102.	2.6	5
115	Multi-walled carbon nanotubes induce airway hyperresponsiveness in human bronchi by stimulating sensory C-fibers and increasing the release of neuronal acetylcholine. Expert Review of Respiratory Medicine, 2021, 15, 1473-1481.	2.5	5
116	Red Blood Cells Elicit Platelet-Dependent Neutrophil Recruitment Into Lung Airspaces. Shock, 2021, 56, 278-286.	2.1	4
117	Realising the potential of various inhaled airway challenge agents through improved delivery to the lungs. Pulmonary Pharmacology and Therapeutics, 2018, 49, 27-35.	2.6	3
118	A peptide derived from chaperonin 60.1, IRL201104, inhibits LPS-induced acute lung inflammation. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 321, L803-L813.	2.9	3
119	Perspectives of Pharmacology over the Past 100 Years. Handbook of Experimental Pharmacology, 2019, 260, 3-16.	1.8	2
120	In-vivo skills and UK competitiveness in biomedical sciences. Lancet, The, 2008, 371, 708-709.	13.7	1
121	Validating 123I-metaiodobenzylguanidine as a platelet marker for non-invasive imaging in rabbits. Journal of Pharmacological and Toxicological Methods, 2011, 63, 69-78.	0.7	1
122	A combined phase I/IIa study of the safety, bronchodilator and bronchoprotective effects of nebulized RPL554, a dual PDE3/4â€inhibitor, in healthy subjects and asthmatics. Clinical and Translational Allergy, 2013, 3, O13.	3.2	1
123	Novel pharmacological approaches to airway and pulmonary vascular disease. Current Opinion in Pharmacology, 2009, 9, 229-230.	3.5	0
124	The role of biomarkers in respiratory disease. Pulmonary Pharmacology and Therapeutics, 2010, 23, 466-467.	2.6	0
125	Editorial overview: Respiratory: Cough: a burning issue. Current Opinion in Pharmacology, 2015, 22, iv.	3.5	0
126	Gustav Born: pioneer in imaging platelet and leukocyte biology. Platelets, 2018, 29, 766-770.	2.3	0

#	Article	IF	Citations
127	An in vitro bioassay for evaluating the effect of inhaled bronchodilators on airway smooth muscle. Pulmonary Pharmacology and Therapeutics, 2020, 63, 101943.	2.6	0
128	Inhaled PDE3/4 inhibitors as novel “bifunctional” drugs for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, SY64-3.	0.0	0
129	Prescribing the right therapy for the treatment of chronic cough: a critical focus on current and investigational options. Expert Opinion on Pharmacotherapy, 2022, , 1-4.	1.8	0
130	Title is missing!. , 2020, 15, e0233644.		0
131	Title is missing!. , 2020, 15, e0233644.		0
132	Title is missing!. , 2020, 15, e0233644.		0
133	Title is missing!. , 2020, 15, e0233644.		0